Mazdutide (10 mg) is a synthetic peptide designed to engage both glucagon-like peptide-1 (GLP-1) and glucagon-related signaling pathways. It incorporates an aminoisobutyric acid (Aib) substitution and a lipid side chain to enhance stability and duration in experimental settings.

Mazdutide research has focused on its role in metabolic signaling, glucose regulation, appetite-related pathways, and energy balance in preclinical and early-stage clinical research models. The product is supplied as a high-purity, lyophilized powder in a 10 mg vial, intended for reconstitution and use in laboratory environments.

Mazdutide (10mg) Key Features & Specs

• Subcategory: Weight Loss & Metabolic Peptides
• Strength: 10 mg
• CAS: 2259884-03-0
• Chemical Formula: C₂₁₀H₃₂₂N₄₆O₆₇
• Molecular Weight: 4563.06 g/mol
• Peptide Sequence: His-{Aib}-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Lys-Tyr-Leu-Asp-Glu-Lys-Lys-Ala-Lys-{AEEA-AEEA-γGlu-Nonadecanoic acid}-Glu-Phe-Val-Glu-Trp-Leu-Leu-Glu-Gly-Gly-Pro-Ser-Ser-Gly-NH₂
• Synonyms: IBI-362, LY-3305677

For laboratory research use only.

Mazdutide (10mg) Research Uses

Mazdutide is studied as a dual-pathway modulator in metabolic research. It combines features of incretin-based peptides and glucagon-related signaling molecules, making it useful for investigating their interaction in energy regulation.

Research has focused on:

• Glucose Regulation: Its influence on glucose handling and insulin-related processes.
• Appetite and Satiety Signaling: Effects on food intake and appetite-related pathways.
• Energy Expenditure: Investigating dual signaling’s effect on energy use and metabolic rate.
• Lipid Metabolism: Its influence on liver fat metabolism and circulating lipid levels.
• Cardio-Metabolic Parameters: Evaluation of blood pressure, lipid profiles, and glycemic indicators.

Mazdutide research also explores how combined receptor activity yields different outcomes than single-pathway peptides. These studies remain in preclinical and early clinical research environments.

Mazdutide (10mg) Insights & Observed Findings

Preclinical and clinical research studies have reported various dosing strategies; all findings below are experimental and should not be interpreted as established clinical outcomes.

In early-phase clinical studies:

• Dose-escalation protocols included increases from 2.5 mg up to 10 mg weekly over several weeks.
• Trials evaluated 3 mg, 6 mg, and 9 mg regimens with titration to assess tolerability and response.
• Study durations ranged from 12 to 24 weeks.

Observed findings include:

• Reductions in body weight of approximately 10%–15% were observed in certain research cohorts under controlled study conditions.
• Decreases in glycated hemoglobin (HbA1c) of 1.4%–1.7% were reported in metabolic research studies under controlled conditions.
• Changes in appetite-related outcomes and energy intake patterns.

In preclinical models:

• Rodent studies used doses up to 100 µg/kg.
• Glucose tolerance, lipid metabolism, and energy expenditure
• Hepatic fat accumulation and metabolic markers were observed.

These findings are derived from controlled research environments and are not intended to represent clinical outcomes. They provide a framework for ongoing investigation into dual-agonist peptide systems.

Mazdutide (10mg) Handling & Storage

• Store the lyophilized peptide at –20°C or below in a sealed vial. Protect from light and moisture.
• Allow the vial to reach room temperature before opening to reduce condensation.
• For reconstitution, use sterile, peptide-compatible solvents such as bacteriostatic water or buffered solutions.
• Reconstituted solutions should be stored at 2–8°C for experimental use.
• For extended research workflows, aliquoting into smaller volumes is recommended to reduce repeated freeze–thaw cycles.
• All handling procedures should follow established laboratory protocols.

Compliance Notice: This product is intended for laboratory research use only and is not approved for human or veterinary use. It is not intended for diagnostic, therapeutic, or clinical applications. Any reference to biological activity or potential effects is based solely on preclinical or in-vitro findings and should not be interpreted as validated clinical outcomes. Researchers are responsible for ensuring proper handling, storage, and disposal in accordance with institutional, federal, and international guidelines.

References

1. Ji L, Jiang H, An P, et al. IBI362 (LY3305677), a weekly-dose GLP-1 and glucagon receptor dual agonist, in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple ascending dose phase 1b study. EClinicalMedicine. 2021;39:101088. doi:10.1016/j.eclinm.2021.101088
2. Ji L, Gao L, Jiang H, et al. Safety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) 9 mg and 10 mg in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple-ascending-dose phase 1b trial. EClinicalMedicine. 2022;54:101691. doi:10.1016/j.eclinm.2022.101691
3. Bhattachar SN, Tham LS, Li Y, et al. Mazdutide reduces body weight in adults with overweight or obesity: A high‐dose Phase 1 trial. Diabetes Obesity and Metabolism. 2025;27(11):6460-6469. doi:10.1111/dom.70040
4. Nalisa DL, Cuboia N, Dyab E, et al. Efficacy and safety of Mazdutide on weight loss among diabetic and non-diabetic patients: a systematic review and meta-analysis of randomized controlled trials. Frontiers in Endocrinology. 2024;15:1309118. doi:10.3389/fendo.2024.1309118
5. Ji L, Jiang H, Cheng Z, et al. A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity. Nature Communications. 2023;14(1):8289. doi:10.1038/s41467-023-44067-4